AIDS-related Kaposi Sarcoma Clinical Trial
Official title:
Phase II Study of Sunitinib (SU11248) in Patients With Kaposi's Sarcoma in East Africa
Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. This phase II trial is studying the side effects and how well sunitinib malate works in treating patients with Kaposi sarcoma.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | |
Est. primary completion date | October 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - ECOG performance status 0-1 - Documented HIV-serostatus [HIV-seronegative (endemic KS) or HIV-seropositive (epidemic/AIDS KS)] - No symptomatic organ involvement, visceral crisis, or life-threatening disease (e.g., extensive or symptomatic pulmonary disease or reticuloendothelial system/hepatic involvement) for which aggressive double- or triple-drug combination chemotherapy for urgent cytoreduction is indicated (i.e., doxorubicin hydrochloride, bleomycin, and vinblastine [ABV], BV, or AV) - Histologically confirmed Kaposi sarcoma - Platelet count > 75,000/uL - Life expectancy >= 24 weeks - Absolute granulocyte count > 1,000/uL - Hemoglobin > 8.0 g/dL OR hematocrit > 24% - Serum creatinine =< 2.0 mg/dL - AST < 3 times normal - Fertile patients must use effective contraception - Normal clinical cardiac examination and normotensive (systolic and diastolic BP < 140/90 mm Hg) documented on at least two occasions prior to enrollment - Normal ECG including QTc interval < 500 msec - Normal echocardiogram prior to enrollment (if feasibly possible) - Must be able to swallow study medication - No acute infections [Patients with chronic infections (e.g., malaria, tuberculosis, parasitic infections, or hepatitis B or C) that may be active but under treatment are allowed provided all eligibility criteria are met] - At least 60 days since prior local treatment modalities (e.g., resection, cryosurgery, radiotherapy, or intralesional therapy) AND treated lesions must have clearly progressed following such therapies if the lesions are to be used as an index lesion - No prior systemic anticancer therapy for Kaposi sarcoma - Concurrent antiretroviral therapy required for HIV-seropositive patients (Patient must be on a stable regimen 8 weeks prior to study enrollment--An exception may be made for patients who have exhausted or are intolerant to all available regimens) - No other concurrent systemic anticancer therapy - Patient resides in Uganda or Kenya, East Africa Exclusion Criteria: - Pregnant or nursing - Baseline diarrhea >= grade 2 by CTCAE - Uncontrolled intercurrent illness including, but not limited to, any of the following: - Ongoing or acute active infection - Symptomatic congestive heart failure (NYHA class III or IV heart disease) - Unstable angina pectoris - Uncontrolled intercurrent illness including, but not limited to, any of the following: 1) Cardiac arrhythmia (i.e., history of serious ventricular arrhythmia, ventricular fibrillation, or ventricular tachycardia >= 3 beats in a row OR QTc >= 500 msec) 2) Psychiatric illness or social situation that would limit compliance with study requirements |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) | National Institute of Allergy and Infectious Diseases (NIAID) |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Response rate | The true response rate will be estimated based on the number of responses using a binomial distribution. The confidence intervals for them can be estimated using same distribution. Chi-square test or Fisher's exact test will be used to examine the difference of response rate between the two cohorts and log-rank test for the difference of survival outcomes. | Up to 11 months | No |
Primary | Overall survival | Will be estimated by Kaplan-Meier method. | From the date of treatment to date of death, assessed up to 11 months | No |
Primary | Progression-free survival | Will be estimated by Kaplan-Meier method. | From the date of treatment to date of death or date of disease progression, assessed up to 11 months | No |
Primary | Levels of plasma-associated HIV-1 RNA viral load and cell-associated KSHV DNA viral load | Multivariate analysis will be performed using the Cox proportional hazards model. The effects of CD4+ lymphocyte counts, plasma HIV-1 RNA viral load and KSHV DNA level on the objective response rate will be evaluated using multivariate logistic regression. | Up to 11 months | No |
Secondary | Changes in CD4+ and CD8+ cell counts, levels of plasma-associated HIV-1 RNA, and cell-associated KSHV DNA load | For each treatment cohort and for all groups combined, the Wilcoxon signed rank test (the non-parametric version of paired T-test) will be used to evaluate the changes. | Baseline and 6 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03596918 -
Evaluating Quality of Life in Patients With AIDS-Associated Kaposi Sarcoma Treated With Bleomycin and Vincristine
|
||
Not yet recruiting |
NCT05567601 -
Doxil/Caelyx BE Study
|
Phase 1 | |
Terminated |
NCT04893018 -
NT-I7 for Kaposi Sarcoma in Patients With or Without HIV
|
Phase 1 | |
Completed |
NCT00064142 -
Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma
|
Phase 2 | |
Terminated |
NCT00020683 -
A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma
|
Phase 2 | |
Completed |
NCT00003350 -
Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma
|
Phase 3 | |
Not yet recruiting |
NCT05411237 -
Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma
|
Phase 3 | |
Active, not recruiting |
NCT05510973 -
Evaluation of Advanced HIV Disease Differentiated Care Model in Malawi
|
N/A | |
Recruiting |
NCT05510908 -
Use of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMC
|
||
Withdrawn |
NCT02137564 -
Gamma Secretase Inhibitor PF-03084014 in Treating Patients With AIDS-Associated Kaposi Sarcoma
|
Phase 2 | |
Completed |
NCT01016730 -
Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma
|
Phase 1 | |
Completed |
NCT01057121 -
Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma
|
Phase 1/Phase 2 |